CRISPR Therapeutics AG (CRSP) stock surged 5.32% in trading on Tuesday, driven by a combination of positive analyst sentiment and a significant purchase by a prominent investment firm. The gene-editing company's shares gained momentum as investors reacted to multiple analyst reports and a large stock acquisition.

Leading the positive sentiment, Chardan Capital reaffirmed its Buy rating on CRISPR Therapeutics with a price target of $82.00, suggesting substantial upside potential. While Barclays and RBC Capital maintained their Hold ratings, their price targets of $56.00 and $42.00 respectively, still indicate room for growth from current levels. The mix of ratings, with a notably bullish outlook from Chardan Capital, appears to have bolstered investor confidence in the company's prospects.

Adding fuel to the rally, Cathie Wood's ARK Investment made a significant move by purchasing 181,300 shares of CRISPR Therapeutics. This large acquisition by a well-known investment firm, known for its focus on innovative and disruptive technologies, likely served as a strong vote of confidence in the company's future. The combination of positive analyst coverage and institutional buying appears to have created a perfect storm for CRISPR Therapeutics' stock, resulting in the impressive 5.32% gain.